Eloralintide vs Cagrilintide
Eloralintide (LY3841136) and Cagrilintide are the two leading long-acting amylin analogues under investigation for obesity. Both belong to the amylin class, but their receptor pharmacology, combination datasets, and developer roadmaps are distinct. This page compares them as research compounds.
Eloralintide 10mg is booked in for a full-panel independent test at Vanguard Laboratory: purity, quantity, endotoxins and sterility. Results from late October, in the COA Library.
| Eloralintide | Cagrilintide | |
|---|---|---|
| Development code | LY3841136 | AM833 |
| Receptor profile | Selective amylin receptor agonist | Dual amylin and calcitonin receptor agonist |
| Administration frequency | Once weekly subcutaneous | Once weekly subcutaneous |
| Lead combination partner | Tirzepatide | Semaglutide (CagriSema) |
| Development stage | ENLIGHTEN Phase 3 programme | Phase 3 alone (RENEW); with semaglutide, under US review |
| Research-grade availability | Factory Direct kits; UK single vials on waitlist |
- Development code
- LY3841136AM833
- Receptor profile
- Selective amylin receptor agonistDual amylin and calcitonin receptor agonist
- Administration frequency
- Once weekly subcutaneousOnce weekly subcutaneous
- Lead combination partner
- TirzepatideSemaglutide (CagriSema)
- Development stage
- ENLIGHTEN Phase 3 programmePhase 3 alone (RENEW); with semaglutide, under US review
- Research-grade availability
Receptor selectivity: why the design choice matters
Amylin signals through a heterodimer of the calcitonin receptor plus a RAMP (receptor activity-modifying protein). Cagrilintide is engineered as a dual agonist that binds both the amylin heterodimer and the calcitonin receptor directly. Eloralintide is engineered for amylin receptor selectivity, minimising calcitonin receptor engagement.
The theoretical benefit of selectivity is a cleaner pharmacological signal and, in Phase 2 Eloralintide data, a gastrointestinal tolerability profile with mild and largely transient nausea in the first weeks of the trial. Whether that translates to a meaningful clinical differentiation in head-to-head work is the question the ENLIGHTEN and REDEFINE programmes are ultimately answering.
Phase 2 efficacy signals
Cagrilintide's 26-week Phase 2 produced dose-dependent body-weight reductions of 6.0% to 10.8%, against 3.0% on placebo. In the 68-week Phase 3 REDEFINE 1 trial, cagrilintide alone reached 11.5% and its combination with Semaglutide (CagriSema) 20.4%, against 3.0% on placebo.
Eloralintide's 48-week Phase 2, published in The Lancet in November 2025, reported 9.5% to 20.1% weight reduction as monotherapy across its dose arms, against 0.4% with placebo. Direct cross-trial numeric comparison is not appropriate given design differences, but both programmes have moved into Phase 3 on the strength of the readouts.
Combination trial design differences
CagriSema (Cagrilintide plus Semaglutide) is the more mature combination programme: its Phase 3 REDEFINE trials are published and it is under review in the US. It pairs a dual amylin/calcitonin agonist with a selective GLP-1 agonist.
Eloralintide plus Tirzepatide is the mirror-image experiment: a selective amylin agonist paired with a dual GLP-1/GIP agonist, three complementary receptor pathways with less overlap than CagriSema. In a 48-week Phase 2b trial in adults with type 2 diabetes, presented at EASD in September 2026, the highest-dose combination reached 23.3% mean weight reduction against 14.8% with Tirzepatide alone.
Bottom line for research labs
For research labs modelling the amylin class today, Cagrilintide is the better-characterised reference compound with the deeper published literature and immediate stock availability. Eloralintide is the more interesting target for novel-mechanism work because the selective amylin design and its combination with Tirzepatide are producing pharmacology distinct from anything previously studied in the class.